CC2D2A

Across TCGA pan-cancer cohorts, CC2D2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CC2D2A data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CC2D2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CC2D2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where CC2D2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.895	0.479	.005	22	view →
CCRCC	DFS	Tertile	III,IV	0.278	1.000	.014	14	view →
GBM	OS	Median	All	0.771	0.914	.003	7	view →
PDAC	OS	Median	II,III,IV	0.671	0.321	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CC2D2A–LUAD (OS)

Open the LUAD breakdown →